Functional genomics for breast cancer drug target discovery.
Journal
Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
30
03
2021
accepted:
05
07
2021
revised:
05
07
2021
pubmed:
22
7
2021
medline:
6
1
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
Breast cancer is a heterogeneous disease that develops through a multistep process via the accumulation of genetic/epigenetic alterations in various cancer-related genes. Current treatment options for breast cancer patients include surgery, radiotherapy, and chemotherapy including conventional cytotoxic and molecular-targeted anticancer drugs for each intrinsic subtype, such as endocrine therapy and antihuman epidermal growth factor receptor 2 (HER2) therapy. However, these therapies often fail to prevent recurrence and metastasis due to resistance. Overall, understanding the molecular mechanisms of breast carcinogenesis and progression will help to establish therapeutic modalities to improve treatment. The recent development of comprehensive omics technologies has led to the discovery of driver genes, including oncogenes and tumor-suppressor genes, contributing to the development of molecular-targeted anticancer drugs. Here, we review the development of anticancer drugs targeting cancer-specific functional therapeutic targets, namely, MELK (maternal embryonic leucine zipper kinase), TOPK (T-lymphokine-activated killer cell-originated protein kinase), and BIG3 (brefeldin A-inhibited guanine nucleotide-exchange protein 3), as identified through comprehensive breast cancer transcriptomics.
Identifiants
pubmed: 34285339
doi: 10.1038/s10038-021-00962-6
pii: 10.1038/s10038-021-00962-6
pmc: PMC8384626
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
927-935Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology (MEXT)
ID : JP20H00543
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 19191248
Informations de copyright
© 2021. The Author(s).
Références
Nat Rev Cancer. 2003 Oct;3(10):781-9
pubmed: 14570045
Dev Dyn. 1999 Aug;215(4):344-51
pubmed: 10417823
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Lancet Oncol. 2018 Jul;19(7):880-888
pubmed: 29804905
Cancer Res. 2006 Sep 15;66(18):9186-95
pubmed: 16982762
Lancet. 2017 Dec 17;388(10063):2997-3005
pubmed: 27908454
Cancer Sci. 2010 Feb;101(2):403-11
pubmed: 19900192
Oncogene. 2008 Sep 25;27(43):5672-83
pubmed: 18542055
Eur J Pharm Sci. 2017 Dec 15;110:51-61
pubmed: 28115222
BMC Res Notes. 2014 Jul 06;7:435
pubmed: 24997568
Oncotarget. 2016 Mar 22;7(12):13621-33
pubmed: 26871945
Clin Cancer Res. 2009 Apr 1;15(7):2552-8
pubmed: 19318484
Cancer. 2019 Nov 15;125(22):3974-3984
pubmed: 31318460
Cancer Sci. 2009 Aug;100(8):1468-78
pubmed: 19496786
Nature. 2004 Mar 25;428(6981):431-7
pubmed: 15042092
Int J Oncol. 2013 Feb;42(2):478-506
pubmed: 23254957
Traffic. 2007 Nov;8(11):1476-85
pubmed: 17850229
Cancer Sci. 2008 Jan;99(1):62-70
pubmed: 17944972
J Biol Chem. 2020 Jun 12;295(24):8195-8203
pubmed: 32350113
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
J Biol Chem. 2000 Nov 17;275(46):35848-56
pubmed: 10960470
Mol Cancer Ther. 2017 Sep;16(9):1843-1854
pubmed: 28655782
Mol Biol Cell. 2004 Apr;15(4):1487-505
pubmed: 14742722
Cancer Biol Med. 2015 Dec;12(4):342-54
pubmed: 26779371
Int J Oncol. 2004 Oct;25(4):797-819
pubmed: 15375528
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6947-52
pubmed: 10359819
Cancer Sci. 2015 May;106(5):550-8
pubmed: 25736224
Nat Commun. 2017 May 30;8:15427
pubmed: 28555617
Nat Commun. 2013;4:2443
pubmed: 24051437
Front Oncol. 2012 Jun 18;2:62
pubmed: 22720269
PLoS One. 2015 Jun 08;10(6):e0127707
pubmed: 26052702
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
DNA Res. 2002 Apr 30;9(2):35-45
pubmed: 12056413
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Oncogene. 2020 May;39(21):4170-4182
pubmed: 32277233
Oncotarget. 2016 Apr 5;7(14):18171-82
pubmed: 26918358
PLoS One. 2014 Apr 16;9(4):e92546
pubmed: 24739874
PLoS One. 2016 Apr 15;11(4):e0153518
pubmed: 27082996
Nature. 1996 Dec 5;384(6608):481-4
pubmed: 8945478
Cancer Res. 2009 Nov 15;69(22):8752-60
pubmed: 19887602
Cancer Res. 2012 Jun 15;72(12):3060-8
pubmed: 22523035
Cancer Med. 2020 Jan;9(1):324-334
pubmed: 31714026
Oncotarget. 2015 Oct 20;6(32):33410-25
pubmed: 26450903
Oncotarget. 2016 Feb 2;7(5):6266-80
pubmed: 26701722
Int J Oncol. 2009 Oct;35(4):673-81
pubmed: 19724902
Breast Cancer Res Treat. 2021 Feb;186(1):265-266
pubmed: 33170437
Int J Oncol. 2010 Oct;37(4):861-7
pubmed: 20811708
Oncotarget. 2012 Dec;3(12):1629-40
pubmed: 23283305
Oncotarget. 2016 Apr 5;7(14):17652-64
pubmed: 26933922
J Biol Chem. 2004 Mar 5;279(10):8642-7
pubmed: 14699119
Cancer Res. 2005 Nov 1;65(21):9751-61
pubmed: 16266996
Cancer Lett. 2016 Dec 1;383(1):85-93
pubmed: 27693640
Mol Cell Biol. 2005 Aug;25(15):6682-93
pubmed: 16024803
Clin Cancer Res. 2010 Mar 1;16(5):1368-72
pubmed: 20179227
Stem Cell Reports. 2015 Feb 10;4(2):226-38
pubmed: 25601206
Sci Transl Med. 2014 Oct 22;6(259):259ra145
pubmed: 25338756
Oncotarget. 2014 Dec 15;5(23):12371-82
pubmed: 25365263
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Dev Biol. 2002 Jan 15;241(2):327-38
pubmed: 11784115
Ann Oncol. 2018 Aug 1;29(8):1748-1754
pubmed: 29893790
Cancer Res. 2010 Apr 1;70(7):2759-69
pubmed: 20215525
J Mol Biol. 2007 Jul 6;370(2):231-45
pubmed: 17512944
Lancet Oncol. 2019 Dec;20(12):1750-1759
pubmed: 31668850
Genes Chromosomes Cancer. 2010 Oct;49(10):861-72
pubmed: 20589935
Cancer Sci. 2009 Aug;100(8):1443-50
pubmed: 19432882
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Breast Cancer Res. 2007;9(1):R17
pubmed: 17280616
Elife. 2017 Mar 24;6:
pubmed: 28337968
CA Cancer J Clin. 2007 Jul-Aug;57(4):190-205
pubmed: 17626117
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Biochem Biophys Res Commun. 2019 Oct 8;518(1):183-189
pubmed: 31421830
Ann Oncol. 2008 Jan;19(1):16-27
pubmed: 17693420
Free Radic Biol Med. 2013 Oct;63:313-24
pubmed: 23747528
J Biol Chem. 2012 Jun 15;287(25):20797-810
pubmed: 22532570
Nature. 2004 Mar 25;428(6981):427-31
pubmed: 15042091
Clin Cancer Res. 2016 Dec 15;22(24):6110-6117
pubmed: 27334838
Clin Cancer Res. 2017 Jul 15;23(14):3529-3536
pubmed: 28053022
Sci Rep. 2017 Feb 14;7:42502
pubmed: 28195154
Bioorg Med Chem. 2017 May 1;25(9):2609-2616
pubmed: 28351607
Cancer Sci. 2007 Feb;98(2):174-81
pubmed: 17233835
J Med Chem. 2016 May 26;59(10):4711-23
pubmed: 27187609
Elife. 2014 May 20;3:e01763
pubmed: 24844244
Methods Mol Biol. 2009;568:37-56
pubmed: 19582420
Cell Rep. 2017 Dec 5;21(10):2829-2841
pubmed: 29212029
Oncotarget. 2016 May 3;7(18):26604-16
pubmed: 27049917
Cancer Res. 2010 Nov 1;70(21):8863-73
pubmed: 20861186
Bioinformatics. 2010 Aug 1;26(15):1841-8
pubmed: 20529890
Clin Cancer Res. 2010 Apr 1;16(7):1979-87
pubmed: 20332324
Trends Cell Biol. 2000 Feb;10(2):60-7
pubmed: 10652516
Sci Rep. 2017 May 12;7(1):1821
pubmed: 28500289
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
J Neurosci Res. 2008 Jan;86(1):48-60
pubmed: 17722061